AbbVie Inc.
https://www.abbvie.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AbbVie Inc.
Dengue Swells As US Vaccine Prospects Recede
Sanofi’s voluntary Dengvaxia withdrawal due to low demand leaves the US with no dengue vaccine, even as Puerto Rico declares a public health emergency and global cases rise.
Amid Growing Pandemic Fears, Moderna Gets BARDA Funding For Flu Program
The biotech got a $176m award for its pandemic influenza vaccine program through BARDA’s Rapid Response Partnership Vehicle.
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Spain's Rovi In Line For €3.4bn Windfall With CDMO Sale
The Madrid-headquartered group could see its finances transformed with a sale of its third party manufacturing services which have blossomed through its partnership with Moderna.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Luminera
- Mavupharma
- Pharmacyclics, Inc.
- Stemcentrx, Inc.
- Syndesi Therapeutics SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice